Moderna, Inc. (MRNA)
The price, the headline numbers and the latest news, in one place.
Moderna, Inc. (MRNA) Stock Price, Analysis & Data
| Bid | 132 |
| Market Cap | 53.7B |
| Revenue (ttm) | 2.23B |
| Net Income (ttm) | -3.15B |
| 1.11 | |
| -7.97 | |
| n/a | |
| -29.99 | |
| P/B (ttm) | 7.95 |
| P/S (ttm) | 24.12 |
| Earnings Date | Nov 5, 2026 |
| Ask | 139.65 |
| Volume | 3,960,102 |
| Avg. Volume (20D) | 16,083,901 |
| Open | 134.60 |
| Previous Close | 135.61 |
| Day's Range | 130.38 - 135.59 |
| 52-Week Range | 22.28 - 176.66 |
| Analyst | Hold |
| Price Target | 125 (-7.15%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zi...
Financial Performance
In 2025, Moderna's revenue was 1.92B, a decrease of -39.92% compared to the previous year's 3.2B. Earnings were -2.82B, a decrease of -20.75%.
Financial StatementsAnalyst Forecast
According to 18 analyst ratings, the average rating for MRNA stock is "Hold". The 12-month stock price forecast is 125, which is downside of 7.15% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $143M misses estimates by $0, with 4.38% YoY growth.
- EPS of -1.97 exceeds estimates by 0.09, with 7.51% YoY growth.
Analysts project revenue of ... Upgrade
